CSTL

Castle Biosciences, Inc. is a commercial-stage diagnostics company focused on developing and commercializing molecular diagnostic tests for dermatologic cancers and other diseases. Headquartered in Friendswood, Texas, the company's flagship products include DecisionDx-Melanoma, a gene expression profile test that predicts metastatic risk in melanoma patients, and DecisionDx-SCC, which assesses squamous cell carcinoma risk. Castle Biosciences also offers tests for uveal melanoma and Barrett's esophagus. The company's proprietary technology helps physicians make more informed treatment decisions by providing personalized risk stratification for cancer patients.